Natco Pharma Limited (NATCOPHARM) - Total Liabilities
Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has total liabilities worth Rs17.76 Billion INR (≈ $192.06 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Natco Pharma Limited (NATCOPHARM) cash flow conversion to assess how effectively this company generates cash.
Natco Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Natco Pharma Limited's assets to evaluate the company's liquid asset resilience ratio.
Natco Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Natco Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Anke BioTech Group
SHE:300009
|
China | CN¥755.64 Million |
|
Shanghai Hanbell Precise Machinery Co Ltd
SHE:002158
|
China | CN¥1.88 Billion |
|
Qingdao Huicheng Environmental Co Ltd
SHE:300779
|
China | CN¥4.46 Billion |
|
Affle (India) Limited
NSE:AFFLE
|
India | Rs6.58 Billion |
|
Park Hotels & Resorts Inc
NYSE:PK
|
USA | $4.62 Billion |
|
Blue Bird Corp
NASDAQ:BLBD
|
USA | $370.97 Million |
|
Bitdeer Technologies Group Class A Ordinary Shares
NASDAQ:BTDR
|
USA | $1.86 Billion |
|
Banque Cantonale du Valais
SW:WKBN
|
Switzerland | CHF20.23 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Natco Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Natco Pharma Limited stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.58 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Natco Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Natco Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Natco Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs10.19 Billion ≈ $110.15 Million |
-3.29% |
| 2024-03-31 | Rs10.53 Billion ≈ $113.90 Million |
-130.26% |
| 2023-03-31 | Rs-34.80 Billion ≈ $-376.35 Million |
-511.59% |
| 2022-03-31 | Rs8.46 Billion ≈ $91.44 Million |
+26.48% |
| 2021-03-31 | Rs6.68 Billion ≈ $72.30 Million |
-16.76% |
| 2020-03-31 | Rs8.03 Billion ≈ $86.85 Million |
-1.11% |
| 2019-03-31 | Rs8.12 Billion ≈ $87.83 Million |
+27.07% |
| 2018-03-31 | Rs6.39 Billion ≈ $69.12 Million |
-3.78% |
| 2017-03-31 | Rs6.64 Billion ≈ $71.83 Million |
+27.59% |
| 2016-03-31 | Rs5.21 Billion ≈ $56.30 Million |
-2.33% |
| 2015-03-31 | Rs5.33 Billion ≈ $57.64 Million |
+15.12% |
| 2014-03-31 | Rs4.63 Billion ≈ $50.07 Million |
-13.68% |
| 2013-03-31 | Rs5.36 Billion ≈ $58.00 Million |
+24.53% |
| 2012-03-31 | Rs4.31 Billion ≈ $46.58 Million |
+21.72% |
| 2011-03-31 | Rs3.54 Billion ≈ $38.27 Million |
+47.28% |
| 2010-03-31 | Rs2.40 Billion ≈ $25.98 Million |
-4.08% |
| 2009-03-31 | Rs2.50 Billion ≈ $27.09 Million |
+28.90% |
| 2008-03-31 | Rs1.94 Billion ≈ $21.01 Million |
+18.65% |
| 2007-03-31 | Rs1.64 Billion ≈ $17.71 Million |
+6.27% |
| 2006-03-31 | Rs1.54 Billion ≈ $16.67 Million |
-11.31% |
| 2005-03-31 | Rs1.74 Billion ≈ $18.79 Million |
-- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more